中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.021 seconds)

    Hydrophobic Active Agent Compositions and Related Methods
    21.
    发明申请
    Hydrophobic Active Agent Compositions and Related Methods 审中-公开
    疏水活性剂组合物及相关方法

    公开(公告)号：US20110142945A1

    公开(公告)日：2011-06-16

    申请号：US13029989

    申请日：2011-02-17

    Applicant: Feng-Jing Chen ,  Kathryn Gutke ,  Srinivasan Venkateshwaran ,  Mahesh V. Patel

    Inventor： Feng-Jing Chen ,  Kathryn Gutke ,  Srinivasan Venkateshwaran ,  Mahesh V. Patel

    IPC: A61K9/14 ,  A61K31/5685

    CPC classification number: A61K38/13 ,  A61K9/4858 ,  A61K9/4866

    Abstract: Compositions and methods for providing hydrophobic active agents in a bioavailable form are disclosed and described. In one aspect of the invention, pharmaceutical composition containing a testosterone ester is provided. The composition includes a testosterone ester in both dissolved form and as undissolved particles and the dissolved form comprises at least 35 wt % of the testosterone ester present in the composition. The composition further includes a solubilizer and a stabilizer.

    Abstract translation: 公开和描述了以生物可利用形式提供疏水性活性剂的组合物和方法。 在本发明的一个方面，提供了含有睾酮酯的药物组合物。 组合物包括溶解形式的睾酮酯和未溶解的颗粒，溶解形式包含组合物中存在的至少35重量％的睾酮酯。 组合物还包括增溶剂和稳定剂。

    ORAL DOSAGE FORMS FOR OXYGEN CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMERS
    25.
    发明申请
    ORAL DOSAGE FORMS FOR OXYGEN CONTAINING ACTIVE AGENTS AND OXYL-CONTAINING POLYMERS 有权
    含有活性剂和含OYYY聚合物的含氧化合物的口服剂型

    公开(公告)号：US20150087666A1

    公开(公告)日：2015-03-26

    申请号：US14555043

    申请日：2014-11-26

    Applicant: Chandrashekar Giliyar ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    Inventor： Chandrashekar Giliyar ,  Satish Kumar Nachaegari ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/485 ,  A61K31/194 ,  A61K31/4402

    CPC classification number: A61K31/485 ,  A61K9/0053 ,  A61K9/2054 ,  A61K31/09 ,  A61K31/137 ,  A61K31/194 ,  A61K31/4402 ,  A61K45/06 ,  A61K2300/00

    Abstract: The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, a tri-oxy active agent, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts. In one embodiment, a pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The total oxyl content of the hydrophilic polymer in the tablet is from about 4×10−4 moles to about 2.0×10−3 moles. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cmax for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cmax provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.

    Abstract translation: 所公开的发明涉及提供具有至少三个含氧基团的活性剂，三氧基活性剂以及第二活性成分的药物片剂。 三种含氧基活性剂的非限制性实例包括愈创甘油醚，可待因，氢可酮及其药学上可接受的盐。 在一个实施方案中，提供了每12小时一次口服给药的药物片剂。 片剂包括第一活性剂，其为三氧基活性剂，第二活性剂和释放速率控制非离子含氧基的亲水性聚合物。 片剂中亲水性聚合物的总氧基含量为约4×10 -4摩尔至约2.0×10 -3摩尔。 片剂是基质片剂，并且在禁食条件下向受试者单剂量施用一种或多种片剂提供了每种第一活性剂和第二活性剂的平均C max，其为相应平均值的70％至135％ Cmax通过在禁食状态下每隔4〜6小时在12小时时间内向受试者施用立即释放的口服剂型，其中在每个活性剂的12小时时间段内施用的累积剂量相当于 药物片剂中的每种活性剂。

    Antioxidant composition for topical/transdermal prevention and treatment of wrinkles
    27.
    发明授权
    Antioxidant composition for topical/transdermal prevention and treatment of wrinkles 有权
    用于局部/透皮预防和治疗皱纹的抗氧化组合物

    公开(公告)号：US06180133B2

    公开(公告)日：2001-01-30

    申请号：US09198734

    申请日：1998-11-24

    Applicant: Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

    Inventor： Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

    IPC: A61K970

    CPC classification number: A61Q19/08 ,  A61F9/04 ,  A61F13/122 ,  A61F2013/00374 ,  A61F2013/00497 ,  A61F2013/00906 ,  A61K8/0208 ,  A61K8/676 ,  A61K8/678 ,  A61K2800/522 ,  Y10S514/844 ,  Y10S514/848 ,  Y10S514/975

    Abstract: An anti-wrinkle skin treating composition comprises a pressure sensitive matrix patch having dissolved in the adhesive a mixture of antioxidants in the form of a Vitamins C ester and Vitamin E. Also preferably dissolved in the adhesive are glycerine and a polydiorganosiloxane adhesion-adjusting agent. Optionally dissolved in the adhesive is also one or more members selected from the group consisting of moisturizing agents, skin collagen synthesis promoting agents and exfoliating agents. When applied to a wrinkled skin area the composition acts to diminish fine wrinkles and improves the overall thickness, elasticity, firmness and smoothness of the skin. The modified adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily removed without causing skin irritation or leaving adhesive residue on the skin.

    Abstract translation: 抗皱皮肤处理组合物包含在维生素C酯和维生素E形式的溶解在粘合剂中的抗氧化剂混合物的压敏基质贴片。还优选溶解在粘合剂中的是甘油和聚二有机硅氧烷粘合调节剂。 任选地溶解在粘合剂中也是选自保湿剂，皮肤胶原合成促进剂和去角质剂的一种或多种。 当应用于起皱的皮肤区域时，组合物起减少细小皱纹的作用，并提高皮肤的整体厚度，弹性，坚固度和平滑度。 贴剂的改性粘合剂性能足以将贴片保持在皮肤上适合推荐的治疗期，同时允许容易地去除贴片而不引起皮肤刺激或在皮肤上留下粘合剂残留物。

    Transdermal drug delivery matrix for coadministering estradiol and another steroid
    28.
    发明授权
    Transdermal drug delivery matrix for coadministering estradiol and another steroid 失效
    用于联合雌二醇和另一种类固醇的透皮药物递送基质

    公开(公告)号：US5783208A

    公开(公告)日：1998-07-21

    申请号：US683892

    申请日：1996-07-19

    Applicant: Srinivasan Venkateshwaran ,  Charles D. Ebert

    Inventor： Srinivasan Venkateshwaran ,  Charles D. Ebert

    IPC: A61K9/70 ,  A61K31/565 ,  A61L15/58 ,  C07J1/00 ,  A61F13/02

    CPC classification number: A61K9/7061 ,  A61K31/565

    Abstract: A matrix type transdermal patch for coadministering estradiol and another steroid wherein the matrix is composed of a N-vinyl-2-pyrrolidone-containing acrylic copolymer pressure sensitive adhesive, estradiol, the other steroid, and optionally a permeation enhancer, and the respective fluxes of estradiol and the other steroid from the matrix are independent of the respective concentrations of the other steroid and estradiol in the matrix.

    Abstract translation: 用于共混雌二醇和另一种类固醇的基质型透皮贴剂，其中基质由含N-乙烯基-2-吡咯烷酮的丙烯酸共聚物压敏粘合剂，雌二醇，另一种类固醇和任选的渗透促进剂组成， 雌二醇和基质中的其他类固醇与基质中其他类固醇和雌二醇的各自浓度无关。

    Iontophoresis device and method using a rate-controlling electrically sensitive membrane
    29.
    发明授权
    Iontophoresis device and method using a rate-controlling electrically sensitive membrane 失效
    离子电渗装置和使用速率控制电敏膜的方法

    公开(公告)号：US5445607A

    公开(公告)日：1995-08-29

    申请号：US962030

    申请日：1992-10-15

    Applicant: Srinivasan Venkateshwaran ,  Daniel C. H. Cheng

    Inventor： Srinivasan Venkateshwaran ,  Daniel C. H. Cheng

    IPC: A61M37/00 ,  A61N1/30

    CPC classification number: A61N1/0444 ,  A61N1/0448

    Abstract: An iontophoresis device comprising a drug reservoir containing the drug in ionic form and in communication with the skin, a skin permeation enhancing agent contained in the reservoir or in a second reservoir also in communication with the skin, an electrode in contact with the drug, another electrode in contact with the skin, a D.C. power source connected to the electrodes and an electrically sensitive membrane interposed between the reservoir and the skin that is impermeable to drug in the absence of a voltage difference between the electrodes and permeable to the drug in the presence of a voltage difference. The skin permeation enhancing agent eliminates the skin as a rate-controlling element, thus making the rate of drug administration dependent upon the membrane permeability, which in turn is controlled electrically.

    Abstract translation: 一种离子电渗疗法装置，其特征在于，包含含有离子形式的药物并与皮肤连通的药物储存器，包含在储存器中的皮肤渗透增强剂或与皮肤相连的第二储存器，与药物接触的电极，另一种 与皮肤接触的电极，连接到电极的DC电源和插入在储存器和皮肤之间的电敏膜，其在不存在电极之间的电压差并且在存在下可渗透的药物时是不可渗透的 的电压差。 皮肤渗透增强剂消除皮肤作为速率控制元件，从而使得药物施用的速率取决于膜渗透性，其又被电控制。

    HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS
    30.
    发明申请
    HIGH-STRENGTH TESTOSTERONE UNDECANOATE COMPOSITIONS 有权
    高强度试验机组合物

    公开(公告)号：US20150224059A1

    公开(公告)日：2015-08-13

    申请号：US14691229

    申请日：2015-04-20

    Applicant: Chandrashekar Giliyar ,  Basawaraj Chickmath ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    Inventor： Chandrashekar Giliyar ,  Basawaraj Chickmath ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    IPC: A61K9/48 ,  A61K31/568

    CPC classification number: A61K31/568 ,  A61K9/0053 ,  A61K9/4858 ,  A61K9/4875 ,  A61K47/12 ,  A61K47/22 ,  A61K47/44 ,  G01N33/743

    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

    Abstract translation: 本公开涉及含有十一酸睾酮的药物组合物和口服剂量胶囊以及相关方法。 胶囊包括胶囊壳和胶囊填充物。 基于总胶囊填充，胶囊填充物可以包含增溶剂和约14重量％至约35重量％的十一酸睾酮。 口服剂量胶囊使得当向男性受试者单次口服给予一种或多种具有总睾酮十一烷酸酯的胶囊剂，每日剂量约350mg至约650mg时，其提供血清睾酮C max与血清睾酮的比例约为 2.7以下。 在另一个实施方案中，提供了一种用于在目标血清睾酮浓度范围内为男性受试者提供睾酮血清浓度的方法。

Patent Agency Ranking